Exact Mass: 441.1779

D000963 - Antimetabolites > D000960 - Hypolipidemic Agents > D054872 - Fatty Acid Synthesis Inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents D009676 - Noxae > D000963 - Antimetabolites D000890 - Anti-Infective Agents

18-Carboxy-dinor-LTE4

(4Z,7Z,9E,11E,13R,14S)-13-{[(2S)-2-amino-2-carboxyethyl]sulfanyl}-14-hydroxyoctadeca-4,7,9,11-tetraenedioic acid

C21H31NO7S (441.1821)

18-carboxy-dinor-LTE4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 18-carboxy-dinor-LTE4 is a metabolite through lipid oxidation of Leukotriene E4 (LTE4).Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078)

6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-5-methyl-8-[2-[(1-oxido-4-quinolinyl)oxy]ethyl]-

4-(2-{2-ethyl-9-methyl-10-oxo-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3(8),4,6,11,13-hexaen-13-yl}ethoxy)quinolin-1-ium-1-olate

Brivanib alaninate

1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-F][1,2,4]triazin-6-yl}oxy)propan-2-yl 2-aminopropanoic acid

C22H24FN5O4 (441.1812)

Db-cAMP

6-[6-(dibutylamino)purin-9-yl]-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol

C18H28N5O6P (441.1777)

Fleephilone

A organic heterotetracyclic compound isolated from the fermentation broth of Trichoderma harzianum and exhibits anti-HIV activity.

(3S,6S)-8-methyl-6-[(phenylcarbonyl)oxy]-8-azabicyclo[3.2.1]oct-3-yl 4-hydroxy-3,5-dimethoxybenzoate|6beta-benzoyloxy-3alpha-(4-hydroxy-3,5-dimethoxybenzoyloxy)tropane

beta-D-fructofuranosyl-(2->1)-alpha-D-[2-O-L-valyl]glucopyranoside

C17H31NO12 (441.1846)

Et glycoside,N-Ac,4,6-dibenzoyl-alpha-D-Pyranose-2-Amino-2,3-dideoxy-ribo-hexopyranose

C24H27NO7

C18H27N5O6S

C18H27N5O6S (441.1682)

Asp Asn Pro Pro

(2S)-1-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-3-carbamoylpropanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

Asp Pro Asn Pro

(2S)-1-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-carboxypropanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanoyl]pyrrolidine-2-carboxylic acid

Asp Pro Pro Asn

(3S)-3-amino-4-[(2S)-2-{[(2S)-2-{[(1S)-2-carbamoyl-1-carboxyethyl]carbamoyl}pyrrolidin-1-yl]carbonyl}pyrrolidin-1-yl]-4-oxobutanoic acid

10-Hydroxydesmethylnortriptyline glucuronide

Asn Asp Pro Pro

(2S)-1-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-carboxypropanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

Asn Pro Asp Pro

(2S)-1-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}-3-carboxypropanoyl]pyrrolidine-2-carboxylic acid

Asn Pro Pro Asp

(2S)-2-{[(2S)-1-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}butanedioic acid

Pro Asp Asn Pro

(2S)-1-[(2S)-3-carbamoyl-2-[(2S)-3-carboxy-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]propanoyl]pyrrolidine-2-carboxylic acid

Pro Asp Pro Asn

(2S)-3-carbamoyl-2-{[(2S)-1-[(2S)-3-carboxy-2-[(2S)-pyrrolidin-2-ylformamido]propanoyl]pyrrolidin-2-yl]formamido}propanoic acid

Pro Asn Asp Pro

(2S)-1-[(2S)-2-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]-3-carboxypropanoyl]pyrrolidine-2-carboxylic acid

Pro Asn Pro Asp

(2S)-2-{[(2S)-1-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanoyl]pyrrolidin-2-yl]formamido}butanedioic acid

Pro Pro Asp Asn

(3S)-3-{[(1S)-2-carbamoyl-1-carboxyethyl]carbamoyl}-3-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}propanoic acid

Pro Pro Asn Asp

(2S)-2-[(2S)-3-carbamoyl-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}propanamido]butanedioic acid

18-carboxy-19,20-dinor-leukotriene E4

(4Z,7Z,9E,11E,13R,14S)-13-(L-cystein-S-yl)-14-hydroxyoctadeca-4,7,9,11-tetraenedioic acid;(4Z,7Z,9E,11E,13R,14S)-13-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-14-hydroxyoctadeca-4,7,9,11-tetraenedioic acid

C21H31NO7S (441.1821)

An icosanoid that is leukotriene E4 in which two methylene groups are removed from the carboxyalkyl chain attached to the non-conjugated double bond.

Nifekalant Hydrochloride

C19H28ClN5O5 (441.1779)

D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents

Brivanib alaninate

Brivanib Alaninate (BMS-582664)

C22H24FN5O4 (441.1812)

C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor

Quetiapine Fumarate

Quetiapine hemifumarate is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine hemifumarate is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine hemifumarate has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[1].

Trequinsin hydrochloride

Tomeglovir

1,3-Pyrrolidinedicarboxylic acid, 4-(1,3-benzodioxol-5-yl)-2-(4-Methoxyphenyl)-, 1-(1,1-diMethylethyl) ester, (2α,3β,4α)-

6H-Dipyrido[3,2-b:2,3-e][1,4]diazepin-6-one, 11-ethyl-5,11-dihydro-5-methyl-8-[2-[(1-oxido-4-quinolinyl)oxy]ethyl]-

Platencin A1

A polycyclic cage that is the 9-hydroxy derivative of platencin. It is isolated from Streptomyces platensis.

2-[[2-(2-Cyanophenoxy)-1-oxoethyl]amino]-5,5,7,7-tetramethyl-4,6-dihydrothieno[2,3-c]pyridine-3-carboxylic acid ethyl ester

2,4-dihydroxy-3-({3-[(2S,3S,4aR,8S,8aR)-3-hydroxy-8-methyl-10-methylidene-7-oxo-1,3,4,7,8,8a-hexahydro-2H-2,4a-ethanonaphthalen-8-yl]propanoyl}amino)benzoic acid

(2r,4s)-2-[(r)-Benzylcarbamoyl-phenylacetyl-methyl]-5,5-dimethyl-thiazolidine-4-carboxylic acid

18-Carboxy-dinor-LTE4

C21H31NO7S (441.1821)

platencin A3

A polycyclic cage that is the 4-hydroxy derivative of platencin. It is isolated from Streptomyces platensis.

2-[3-[3-[3-(1-Imidazolyl)propyl]-4-oxo-2-quinazolinyl]propyl]isoindole-1,3-dione

N-(3-methylphenyl)-4-[4-(4-morpholinyl)-3-nitrophenyl]-1-phthalazinamine

N-tert-butyl-2-[[5-(3,5-dimethoxyphenyl)-1,3,4-oxadiazol-2-yl]thio]-N-(phenylmethyl)acetamide

(2S,3S,3aR,9bR)-1-[(2-chlorophenyl)methyl]-3-(hydroxymethyl)-2-[oxo(1-piperidinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one

1-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-[4-(trifluoromethyl)phenyl]urea

1-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-[4-(trifluoromethyl)phenyl]urea

1-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-[4-(trifluoromethyl)phenyl]urea

(1R,2aR,8bR)-N-(3-chlorophenyl)-1-(hydroxymethyl)-2-(4-oxanylmethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide

(2R,3R,3aS,9bS)-1-[(2-chlorophenyl)methyl]-3-(hydroxymethyl)-2-[oxo(1-piperidinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one

1-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-[4-(trifluoromethyl)phenyl]urea

1-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-[4-(trifluoromethyl)phenyl]urea

1-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-[4-(trifluoromethyl)phenyl]urea

1-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-[4-(trifluoromethyl)phenyl]urea

(1S,2aS,8bS)-N-(3-chlorophenyl)-1-(hydroxymethyl)-2-(4-oxanylmethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide

(1S,2aR,8bR)-N-(3-chlorophenyl)-1-(hydroxymethyl)-2-(4-oxanylmethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide

(1R,2aS,8bS)-N-(3-chlorophenyl)-1-(hydroxymethyl)-2-(4-oxanylmethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide

[(1S)-7-methoxy-9-methyl-1-(3-methylphenyl)sulfonyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol

[(1R)-7-methoxy-9-methyl-1-(4-methylphenyl)sulfonyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol

[(1S)-7-methoxy-9-methyl-1-(4-methylphenyl)sulfonyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol

(1R,9S,10S,11S)-12-[(3-chlorophenyl)methyl]-N-ethyl-10-(hydroxymethyl)-6-oxo-5-[(E)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

(2R,3R,3aS,9bS)-1-[(2-chlorophenyl)methyl]-N-ethyl-3-(hydroxymethyl)-6-oxo-7-[(Z)-prop-1-enyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

(1S,9R,10R,11R)-12-[(3-chlorophenyl)methyl]-N-ethyl-10-(hydroxymethyl)-6-oxo-5-[(E)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

(2S,3S,3aR,9bR)-1-[(2-chlorophenyl)methyl]-N-ethyl-3-(hydroxymethyl)-6-oxo-7-[(Z)-prop-1-enyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

5-aminopentyl 6-O-alpha-D-glucopyranuronosyl-alpha-D-glucopyranoside

C17H31NO12 (441.1846)

Lnaps 4:0/N-7:0

Lnaps 8:0/N-3:0

Lnaps 7:0/N-4:0

Lnaps 9:0/N-2:0

Lnaps 3:0/N-8:0

Lnaps 2:0/N-9:0

Lnaps 5:0/N-6:0

Lnaps 6:0/N-5:0

2-Amino-3-[(3-butanoyloxy-2-heptanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid

2-Amino-3-[hydroxy-(2-octanoyloxy-3-propanoyloxypropoxy)phosphoryl]oxypropanoic acid

2-Amino-3-[(2-hexanoyloxy-3-pentanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid

3-[(3-Acetyloxy-2-nonanoyloxypropoxy)-hydroxyphosphoryl]oxy-2-aminopropanoic acid

Platensimycin